



**Dermot P.B. McGovern, MBBS, D. Phil (Oxon), FRCP (Lon), FACG, AGAF**

Director, Translational Medicine, F. Widjaja Inflammatory Bowel Disease Institute;  
Director, Precision Health Initiative; Professor of Medicine and Biomedical Sciences;  
Joshua L. and Lisa Z. Greer Endowed Chair in IBD Genetics;  
Cedars-Sinai Medical Center, CA

Dr. Dermot McGovern is a gastroenterologist and clinician scientist with an international reputation for excellence in the inflammatory bowel diseases (IBDs). He completed his medical degree at St Mary's Hospital Medical School in London and a gastroenterology fellowship at the University of Oxford. While in Oxford, Dr. McGovern obtained a PhD in complex disease genetics under the supervision of Professor Derek Jewell at the Wellcome Trust Centre for Human Genetics. He was a Senior Lecturer at Imperial College, London, before moving to Cedars-Sinai Medical Center in Los Angeles where he is currently a Professor of Medicine and Biomedical Science, the Director of Translational Medicine at the F. Widjaja Inflammatory Bowel Disease Institute, and he also directs the Cedars-Sinai Precision Medicine Initiative. Dr. McGovern holds the Joshua and Lisa Greer Endowed Chair in IBD Genetics and was honored to be elected to the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP), and the Royal College of Physicians, London.

Dr. McGovern has held leadership positions in several professional organizations including the Crohn's and Colitis Foundation and the American Gastroenterology Association, in addition to providing leadership in national and international consortia including the NIDDK IBD Genetics Consortium, the International IBD Genetics Consortium, the Human Microbiome Project, the Very Early Onset IBD Consortium, and SHARE.

Dr. McGovern's clinical interests include the extra-intestinal complications of IBD and the overlap between IBD and other immune-mediated and metabolic diseases. His group has received funding from the NIH, the Helmsley Charitable Trust, the European Union, the Litwin Foundation, the Paul G. Allen Family Foundation, and the Crohn's and Colitis Foundation of America. His group's overall research aims are to identify molecular signatures associated with the clinical heterogeneity observed in IBD. To achieve this, the McGovern lab utilizes advanced analytic and AI capabilities to decipher data generated using cutting edge technologies including genomics, transcriptomics, and proteomics and now extending to single cell technologies. 'Phenotyping' efforts include radiomics and machine-learning in histopathology as well as more traditional

clinical phenotypes such as disease behavior, response to therapy, and presence of extra-intestinal manifestations.

Dr. McGovern is currently leading an international effort to develop a new classification for IBD. The goal of his group is to influence clinical practice and improve the quality of life for people with IBD by identifying biomarkers and novel opportunities for therapeutic intervention. The group have contributed to significant advances in this area by identification of biomarkers associated with disease progression; immunogenicity to anti-TNFs; life-threatening toxicity to thiopurines; and VEO IBD genes, among others. His group collaborated in the identification of a novel therapeutic target that is currently in phase 3 studies having demonstrated benefit for people with ulcerative colitis and Crohn's disease in phase 2 studies. Dr. McGovern has published over 300 peer-reviewed papers.

Extending the diversity of research is a priority for Dr. McGovern's group who have co-led seminal IBD gene discovery studies in African-American, Hispanic, East Asian, and Ashkenazi Jewish populations, as well as performing the first large-scale study to determine sex-specific effects on the development and presentation of IBD. Dr. McGovern recently returned to Zambia, where he was born, to found the African IBD Research Endeavour (AIRE) a multi-national collaborative effort to study gene and environmental factors influencing the development of IBD in Sub-Saharan Africa.

Dr. McGovern received the Sherman Prize for Excellence in Crohn's and colitis in 2024.